“Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV nonsmall-cell lung cancer: A retrospective study”, Clinics, vol. 76, p. e2251, Nov. 2021, doi: 10.6061/clinics/2021/e2251.